Patent application number | Description | Published |
20100222269 | IMPROVED DERIVATIVES OF AMYLIN - The invention relates to derivatives of human amylin or analogues thereof which bind to the amylin receptor and are linked to an albumin binding compound, pharmaceutical compositions comprising these derivatives and methods for obtaining such. | 09-02-2010 |
20100261637 | PEPTIDES DERIVATIZED WITH A-B-C-D- AND THEIR THERAPEUTICAL USE - The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B-C-, or A-B-C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 10-14-2010 |
20100317057 | SEMI-RECOMBINANT PREPARATION OF GLP-1 ANALOGUES - A semi-recombinant method for the production of GLP-1 analogues and derivatives with non-proteogenic amino acids in the N-terminal part combining the use of recombinant expression techniques and chemical peptide synthesis. | 12-16-2010 |
20110082079 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE - The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 04-07-2011 |
20110105394 | Amylin Derivatives - The present invention relates to novel amylin derivatives, pharmaceutical compositions containing such derivatives and to methods of treating diabetes and hyperglycaemia using the amylin derivatives of the invention. | 05-05-2011 |
20110152183 | DERIVATISED HYBRID PEPTIDES OF AMYLIN AND SALMON CALCITONIN - Described are derivatives of hybrid peptides and pharmaceutical compositions comprising such, wherein said hybrid peptides comprise the C-terminal end of the human amylin peptide sequence, the middle portion of the salmon calcitonin peptide sequence and the N-terminal end of the human amylin peptide sequence, and wherein an albumin binding moiety is attached to the hybrid peptide, optionally via a linker. | 06-23-2011 |
20120245083 | Derivatives of CGRP - Acylated CGRP compounds with a linker have prolonged action and are valuable as medicaments. | 09-27-2012 |
20130005646 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-03-2013 |
20130012427 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-10-2013 |
20130059770 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 03-07-2013 |
20130079278 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 03-28-2013 |
20130143798 | NOVEL GLUCAGON ANALOGUES - The present invention relates to novel peptide compounds which have an improved physical stability in solution and improved solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 06-06-2013 |
20130281363 | POLYPEPTIDES - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 10-24-2013 |
20130288958 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides, to the use of said glucagon peptides in therapy, to methods of treatment comprising administration of said glucagon peptides to patients in need thereof, and to the use of said glucagon peptides in the manufacture of medicaments. The glucagon peptides of the present invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 10-31-2013 |
20130288960 | Double-Acylated GLP-1 Derivatives - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1 (7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1 (7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from Chem. 1, Chem. 2, and Chem. 3: Chem.: HOOC—(CH | 10-31-2013 |
20130338068 | DOUBLE-ACYLATED GLP-1 DERIVATIVES WITH A LINKER - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 18 of GLP-1(7-37) (SEQ ID NO: 1), a second K residue at another position, and a maximum of twelve amino acid changes as compared to GLP-1(7-37); which derivative comprises two protracting moieties attached to said first and second K residue, respectively, via a linker, wherein the protracting moiety is selected from | 12-19-2013 |
20140011732 | Peptides Derivatized with A-B-C-D- and their Therapeutical Use - The invention relates to protracted peptide derivatives such as Glucagon-Like Peptide-1 (GLP-1), exendin-4, and analogues thereof, as well as therapeutic uses thereof. The peptide derivative of the invention comprises a peptide wherein at least one amino acid residue is derivatized with A-B—C—, or A-B—C-D-. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, have a low ratio of binding affinity to the GLP-1 receptor in the presence of high/low albumin concentrations, have long half-lives, and have a high affinity of binding to albumin, all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 01-09-2014 |
20140018286 | AMYLIN ANALOGUES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of pramlintide, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 01-16-2014 |
20140031278 | Novel Glucagon Analogues - The present invention relates to novel glucagon peptides with improved stability and solubility at neutral pH, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The glucagon peptides of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity. | 01-30-2014 |
20140087995 | Polypeptides - The invention relates to polypeptides comprising an amino acid sequence which is an analogue of human amylin, pharmaceutical compositions comprising these polypeptides, and these polypeptides for use as medicaments. | 03-27-2014 |
20140088005 | DOUBLE-ACYLATED GLP-1 DERIVATIVES - The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K | 03-27-2014 |
20150025003 | GLUCAGON-LIKE PEPTIDE-1 DERIVATIVES AND THEIR PHARMACEUTICAL USE - The invention relates to protracted Glucagon-Like Peptide-1 (GLP-1) derivatives and therapeutic uses thereof. The GLP-1 derivative of the invention comprises a modified GLP-1(7-37) sequence having a total of 2-12 amino acid modifications, including Glu22 and Arg26, and being derivatised with an albumin binding residue or pegylated in position 18, 20, 23, 30, 31, 34, 36, 37, or 39. These compounds are useful in the treatment or prevention of diabetes type 2 and related diseases. The compounds are potent, stable, have long half-lives, a high affinity of binding to albumin, and/or a high affinity of binding to the extracellular domain of the GLP-1 receptor (GLP-1R), all of which is of potential relevance for the overall aim of achieving long-acting, stable and active GLP-1 derivatives with a potential for once weekly administration. | 01-22-2015 |
Patent application number | Description | Published |
20080226923 | Weldable Corrosion-Protective Agent and Binder Therefor - The invention relates to a binding agent comprising at least one titanium and/or one zircon compound (at least 0.5 wt. % in relation to 100 wt. % binding agent), at least one organo-functional silan, in particular, a monosilan, and a solution. The invention is characterised in that the binding agent comprises at least one fluorinated polymer which is insoluble in the binding agent solution. The invention also relates to a corrosion protection agent which is produced using the binding agent and a weldable corrosion protection agent, in addition to a workpiece which is coated with the inventive corrosion protection agent. | 09-18-2008 |
20080234417 | Microcoating Comprising Siloxanes - The invention relates to a binding agent comprising an aqueous, film-forming, polymeric siloxane. The invention also relates to a coating agent that is produced using said binding agent and to a workpiece that is coated with said coating agent. | 09-25-2008 |
20100108527 | DRUM AND METHOD FOR COATING WORKPIECES WITH A NON-METALLIC COATING - The invention relates to a drum which has a wall, wherein at least the inside of the wall is provided with a surface of insulating material, an opening, defined by wall segments of the wall, radially spaced from one another with respect to a central rotational axis of the drum, and a drive mechanism for rotating the drum in a first or in a second direction, wherein at least one first electrode is arranged on the inside of the wall, and wherein at least one counter electrode is arranged on or between a central axis of the drum and the wall, and a method for coating workpieces. | 05-06-2010 |
20100221568 | Silicon-Based Anticorrosive Agent - The invention relates to an anticorrosive agent comprising zinc dust, and a second component, an organic binder and a VOC-free or VOC-compatible solvent. In order to allow the metal workpieces to be coated in a reliable and energy-saving manner at constant quality, the binder comprises silicon dioxide and alkali silicate in a molar ratio of at least 4:1. The invention also relates to a device for mixing and metering solid and liquid components of an anticorrosive agent. Said device comprises means for metering the quantities of the respective components of the anticorrosive agent, a solution tank and a mixing device. An application system for applying the anticorrosive agent to a workpiece comprises a solution tank, feeding means, at least one pressure reducer connected to the solution tank and at least one spraying device connected to the solution tank. | 09-02-2010 |
20110000793 | COATING METHOD FOR A WORKPIECE - The invention relates to a coating method for a workpiece, including the following method steps: a) applying a coating liquid to the workpiece, wherein the coating liquid comprises an ionic liquid containing ions of at least one element, b) electrochemically depositing a layer of the at least one element from the coating liquid on the workpiece, c) removing the workpiece from the coating liquid, d) removing excess coating liquid from the workpiece. In order to suggest an industrially suitable coating process, particularly for workpieces having at least a partial metal surface, using stable, durable baths, it is provided that the temperature of the workpiece is set such that the temperature of the coating liquid deviates by no more than 10° C. from a predetermined set temperature during the coating process | 01-06-2011 |
20110045309 | METHOD FOR ADJUSTING THE FRICTION COEFFICIENT OF A METALLIC WORKPIECE - The invention relates to a method for adjusting the friction coefficient of the surface of a metallic workpiece by applying and hardening a single-layer or multi-layer coating having a boundary surface facing toward the workpiece and having a boundary surface facing away from the workpiece, wherein one or more base coats each having at least one binding agent and metallic particles, is/are applied in layers, and at least one of the base coats has at least one lubricant. For proposing a possibility for the efficient use of lubricant in anti-corrosion coatings, it is provided that the friction coefficient is adjusted by a lubricant concentration and/or a lubricant composition on the boundary surface facing toward the workpiece that is different from that on the boundary surface facing away from the workpiece | 02-24-2011 |
20120183791 | METHOD FOR APPLYING AT LEAST ONE ANTI-CORROSIVE, LIQUID COATING AGENT COMPRISING METAL PARTICLES TO A WORKPIECE, AND DEVICE THEREFOR - A method for applying at least one anticorrosive, liquid, metal-particle-containing coating agent to a workpiece ( | 07-19-2012 |